Limits...
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.

Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE - J Hematop (2008)

Bottom Line: Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively).No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes.We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.

ABSTRACT
Aurora kinase A, also known as aurora A, is a serine/threonine kinase that plays critical roles in mitosis entry, chromosome alignment, segregation, and cytokinesis. Overexpression of aurora A has been observed in many solid tumors and some hematopoietic neoplasms, but little is known about its expression in myeloid diseases. Because cytogenetic abnormalities play an essential role in the pathogenesis of myeloid malignancies, we hypothesized that aurora A deregulation may be involved in myelodysplastic syndromes and acute myeloid leukemia and contribute to the chromosomal instability observed in these diseases. We assessed aurora A mRNA levels in CD34(+) bone marrow blasts from nine patients with acute myeloid leukemia, 20 patients with myelodysplastic syndromes, and five normal patients serving as controls. CD34(+) blasts were isolated from bone marrow aspirate specimens using magnetic activated cell separation technology. RNA was extracted from purified CD34(+) cells, and quantitative real-time reverse transcriptase polymerase chain reaction for aurora A was performed. Immunocytochemical analyses for total aurora A, phosphorylated aurora A, Ki-67, and activated caspase 3 were performed on cytospin slides made from purified CD34(+) cells in myelodysplastic syndrome patients using standard methods. Aurora A mRNA and protein levels were correlated, as was aurora A mRNA level, with blast counts, cytogenetic abnormalities, and International Prognostic Scoring System score. We found that CD34(+) cells in myelodysplastic syndromes and acute myeloid leukemia expressed aurora A at significantly higher levels (P = 0.01 and P = 0.01, respectively) than normal CD34(+) cells. Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively). No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes. We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

No MeSH data available.


Related in: MedlinePlus

Immunocytochemical stains. Mononuclear CD34+ cells isolated from control (a) or MDS patients (b); total AA in normal control specimens (c) and in MDS patient specimens (d); pAA in normal controls (e) and in MDS cases (f); proliferative Ki-67+ cells (g) and apoptotic active caspase 3+ cells (h) in MDS cases
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2713495&req=5

Fig2: Immunocytochemical stains. Mononuclear CD34+ cells isolated from control (a) or MDS patients (b); total AA in normal control specimens (c) and in MDS patient specimens (d); pAA in normal controls (e) and in MDS cases (f); proliferative Ki-67+ cells (g) and apoptotic active caspase 3+ cells (h) in MDS cases

Mentions: To validate that the purified mononuclear cells had numerous blasts, anti-CD34 antibody was used for immunostaining. Figure 2a, b shows that most (∼80%) of the mononuclear cells isolated from control (Fig. 2a) or MDS patients (Fig. 2b) were blasts immunoreactive with CD34.Fig. 2


Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.

Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE - J Hematop (2008)

Immunocytochemical stains. Mononuclear CD34+ cells isolated from control (a) or MDS patients (b); total AA in normal control specimens (c) and in MDS patient specimens (d); pAA in normal controls (e) and in MDS cases (f); proliferative Ki-67+ cells (g) and apoptotic active caspase 3+ cells (h) in MDS cases
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2713495&req=5

Fig2: Immunocytochemical stains. Mononuclear CD34+ cells isolated from control (a) or MDS patients (b); total AA in normal control specimens (c) and in MDS patient specimens (d); pAA in normal controls (e) and in MDS cases (f); proliferative Ki-67+ cells (g) and apoptotic active caspase 3+ cells (h) in MDS cases
Mentions: To validate that the purified mononuclear cells had numerous blasts, anti-CD34 antibody was used for immunostaining. Figure 2a, b shows that most (∼80%) of the mononuclear cells isolated from control (Fig. 2a) or MDS patients (Fig. 2b) were blasts immunoreactive with CD34.Fig. 2

Bottom Line: Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively).No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes.We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.

ABSTRACT
Aurora kinase A, also known as aurora A, is a serine/threonine kinase that plays critical roles in mitosis entry, chromosome alignment, segregation, and cytokinesis. Overexpression of aurora A has been observed in many solid tumors and some hematopoietic neoplasms, but little is known about its expression in myeloid diseases. Because cytogenetic abnormalities play an essential role in the pathogenesis of myeloid malignancies, we hypothesized that aurora A deregulation may be involved in myelodysplastic syndromes and acute myeloid leukemia and contribute to the chromosomal instability observed in these diseases. We assessed aurora A mRNA levels in CD34(+) bone marrow blasts from nine patients with acute myeloid leukemia, 20 patients with myelodysplastic syndromes, and five normal patients serving as controls. CD34(+) blasts were isolated from bone marrow aspirate specimens using magnetic activated cell separation technology. RNA was extracted from purified CD34(+) cells, and quantitative real-time reverse transcriptase polymerase chain reaction for aurora A was performed. Immunocytochemical analyses for total aurora A, phosphorylated aurora A, Ki-67, and activated caspase 3 were performed on cytospin slides made from purified CD34(+) cells in myelodysplastic syndrome patients using standard methods. Aurora A mRNA and protein levels were correlated, as was aurora A mRNA level, with blast counts, cytogenetic abnormalities, and International Prognostic Scoring System score. We found that CD34(+) cells in myelodysplastic syndromes and acute myeloid leukemia expressed aurora A at significantly higher levels (P = 0.01 and P = 0.01, respectively) than normal CD34(+) cells. Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively). No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes. We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

No MeSH data available.


Related in: MedlinePlus